Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2539560 | 0.85 | CNR1 (0.60) | CNR1CYP1A2CYP2C19 | |
| SCHEMBL4513915 | 0.82 | CNR1 (0.44) | CNR1DPP4CYP1A2CYP2C19KDM4E | |
| SCHEMBL2539570 | 0.77 | MAPT (0.43) | CNR1DPP4KDM4EHSD17B10 | |
| SCHEMBL2539520 | 0.76 | CNR1 (0.45) | CNR1DPP4KDM4EHSD17B10 | |
| SCHEMBL2536778 | 0.75 | CNR1 (0.48) | CNR1 | |
| SCHEMBL2535608 | 0.74 | CNR1 (0.62) | CNR1 | |
| SCHEMBL2541063 | 0.74 | GABRA2 (0.44) | CNR1DPP4KDM4EHSD17B10 | |
| SCHEMBL4513922 | 0.74 | CNR1 (0.38) | CNR1DPP4CYP1A2CYP2C19KDM4E | |
| SCHEMBL2906434 | 0.71 | HSD11B1 (0.47) | CNR1 | |
| SCHEMBL2535613 | 0.70 | CNR1 (0.44) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044072-B2 | Pyrrole derivatives, preparation thereof and therapeutic use thereof | SANOFI AVENTIS (FR) | 2011-10-25 | — | — | US | disclosed |
| US-20090281116-A1 | PYRROLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281116-A1 | PYRROLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | PRMT9, PYCR1, EPOR | CNR1 177/4885DPP4 3530/4885CYP1A2 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.